5Lasota J,Miettinen M.Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours[J].Histopathology,2008(3):245-266.
6Greenson JK.Gastrointestinal stromal tumours and other mesenchymal lesions of the gut[J].Mod Pathol,2003(16):366-375.
7The ESMO/European Sarcoma Network Working Group.Gastrointestinal stromal tumours:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2012,23(Suppl 7):49-55.
8Schlemmer M,Bauer S,Schütte R,et al.Activity and side effects of imatinib in patients with gastrointestinal stromal tumors:data from a German multicenter trial[J].Eur J Med Res,2011,16(5):206-212.
9AD Colevas,A Setser.The NCI Common Terminology Criteria for Adverse Events(CTCAE)v3.0 is the new standard for oncology clinical trials[J].Journal of Clinical Oncology,2004,22(14):6098-6098.
10Demetri G D,von Mehren M,Blanke C D,et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J].N Engl J Med,2002,347(7):472-480.
